Cathepsin B Inhibition Limits Bone Metastasis in Breast Cancer

Authors:
  • GBGalia Blum
    Galia Blum
  • MSMansoureh Sameni
    Mansoureh Sameni
  • CSClare Slaney
    Clare Slaney
  • AAArulselvi Anbalagan
    Arulselvi Anbalagan
  • MOMary B. Olive
    Mary B. Olive
  • BBBradley N. Bidwell
    Bradley N. Bidwell
  • LWLing Wang
    Ling Wang
  • KMKamiar Moin
    Kamiar Moin
  • BSBonnie F. Sloane
    Bonnie F. Sloane

Abstract
Metastasis to bone is a major cause of morbidity in breast cancer patients, emphasizing the importance of identifying molecular drivers of bone metastasis for new therapeutic targets. The endogenous cysteine cathepsin inhibitor stefin A is a suppressor of breast cancer metastasis to bone that is coexpressed with cathepsin B in bone metastases. In this study, we used the immunocompetent 4T1.2 model of breast cancer which exhibits spontaneous bone metastasis to evaluate the function and therapeutic targeting potential of cathepsin B in this setting of advanced disease. Cathepsin B abundancy in the model mimicked human disease, both at the level of primary tumors and matched spinal metastases. RNA interference–mediated knockdown of cathepsin B in tumor cells reduced collagen I degradation in vitro and bone metastasis in vivo. Similarly, intraperitoneal administration of the highly selective cathepsin B inhibitor CA-074 reduced metastasis in tumor-bearing animals, a reduction that was not reproduced by the broad spectrum cysteine cathepsin inhibitor JPM-OEt. Notably, metastasis suppression by CA-074 was maintained in a late treatment setting, pointing to a role in metastatic outgrowth. Together, our findings established a prometastatic role for cathepsin B in distant metastasis and illustrated the therapeutic benefits of its selective inhibition in vivo. Cancer Res; 72(5); 1199–209. ©2012 AACR.

This publication has 50 references indexed in Scilit: